Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Topics: 

Citation
Mahaffey KW et al. Circulation 2019.140(9):739-750.